Abstract: The present invention relates to methods for myelin basic protein detection comprises identifying a subject at risk of or diagnosed with a myelin-associated neuropathy, parenterally administering to the subject the agent, and determining myelination in the subject by detecting binding to myelin basic protein. Methods for the detection of myelin and a quantitative measurement of its local concentration in a sample using an agent with specific binding to myelin basic protein are also provided as is a kit containing the agent or its derivatives for use in detecting myelin basic protein.

Abstract: The present invention relates to methods for imaging annulus fibrosus tissue and a quantitative measurement of its local concentration in a sample using an agent comprising the compound of Formula I, a 13C or 2H enriched compound of Formula I, an 19F-labeled derivative of Formula I, a metal-DOTA (1,4,7,10-tetra-azacyclododecane-N,N?,N?,N??-tetraacetic acid) complex of Formula I, or a radioisotope derivative of Formula I.

Abstract: The present invention relates to a method of in vivo optical imaging, of the margins around tumours, which comprises an optical imaging contrast agent. The optical imaging agents comprise conjugates of near-infrared dyes with synthetic polyethylene glycol (PEG) polymers having a molecular weight in the range 15-45 kDa. Also disclosed are optical imaging contrast agents, pharmaceutical compositions and kits.

Abstract: The present invention relates to methods for the detection of myelin and a quantitative measurement of its local concentration in a sample using a benzofuran compound or its radioisotope derivatives. In one embodiment a method of myelin detection comprises identifying a subject at risk of or diagnosed with a myelin-associated neuropathy, parenterally administering to the subject the benzofuran compound, or a derivative of the compound, and determining myelination in the subject by detecting binding in the sample. In one embodiment, the invention provides a method of imaging myelinated tissue in a surgical field of mammalian tissue comprising the steps of contacting the surgical site with the benzofuran compound or a radioisotope derivative of the compound, and detecting binding in the surgical site.

Abstract: The present invention relates to methods for the detection of myelin and a quantitative measurement of its local concentration in a sample using a benzofuran compound or its radioisotope derivatives. In one embodiment a method of myelin detection comprises identifying a subject at risk of or diagnosed with a myelin-associated neuropathy, parenterally administering to the subject the benzofuran compound, or a derivative of the compound, and determining myelination in the subject by detecting binding in the sample. In one embodiment, the invention provides a method of imaging myelinated tissue in a surgical field of mammalian tissue comprising the steps of contacting the surgical site with the benzofuran compound or a radioisotope derivative of the compound, and detecting binding in the surgical site.

Abstract: The present invention relates to methods for myelin basic protein detection comprises identifying a subject at risk of or diagnosed with a myelin-associated neuropathy, parenterally administering to the subject the agent, and determining myelination in the subject by detecting binding to myelin basic protein.

Abstract: Provided herein are agents that bind to soluble beta-amyloid. Also provided are in vivo and in vitro methods for detecting soluble beta-amyloid in a sample that may include brain tissue.

Abstract: The present invention relates to methods for imaging annulus fibrosus tissue and a quantitative measurement of its local concentration in a sample using an agent comprising the compound of Formula I, a 13C or 2H enriched compound of Formula I, an 19F-labeled derivative of Formula I, a metal-DOTA (1,4,7,10-tetra-azacyclododecane-N,N?,N?,N??-tetraacetic acid) complex of Formula I, or a radioisotope derivative of Formula I.

Abstract: Provided herein are amyloid-binding assays that simulate in situ brain conditions by combining binders with various A-beta species on mammalian brain tissue. In general the amyloid-binding assays comprise the steps of (a) contacting a mammalian brain tissue sample with at least one A-beta species; (b) applying a putative binder to the brain tissue sample; and (c) determining whether the putative binder binds to the A-beta species.

Abstract: In one aspect, the present invention provides a functionalized monodisperse polylysine comprising a linear monodisperse polylysine chain comprising constituent lysine monomer residues containing appended C4-C24 polyethylene glycol groups and at least one appended fluorescent dye moiety is provided.

Abstract: The present disclosure generally relates to systems and methods for identifying the boundaries of tumors and assessing quantitatively the ability of dyes to highlight a tumor's boundary. In accordance with these methods and systems, images are taken of subjects administered agents labeled with dyes. After accessing the images, tumors are selected and routines employed to both identify the boundaries of the tumors, as well as, to quantify various aspects of the tumor boundaries. From these quantifiable descriptors the performances of the various dyes to highlight the boundaries of tumors are evaluated.

Abstract: The present invention relates to methods for the detection of myelin and a quantitative measurement of its local concentration in a sample using a benzofuran compound or its radioisotope derivatives. In one embodiment a method of myelin detection comprises identifying a subject at risk of or diagnosed with a myelin-associated neuropathy, parenterally administering to the subject the benzofuran compound, or a derivative of the compound, and determining myelination in the subject by detecting binding in the sample. In one embodiment, the invention provides a method of imaging myelinated tissue in a surgical field of mammalian tissue comprising the steps of contacting the surgical site with the benzofuran compound or a radioisotope derivative of the compound, and detecting binding in the surgical site.

Abstract: Provided herein are amyloid-binding assays that simulate in situ brain conditions by combining binders with various A-beta species on mammalian brain tissue. In general the amyloid-binding assays comprise the steps of (a) contacting a mammalian brain tissue sample with at least one A-beta species; (b) applying a putative binder to the brain tissue sample; and (c) determining whether the putative binder binds to the A-beta species.